Alnylam Pharmaceuticals
ALNY
#601
Rank
โ‚ฌ31.45 B
Marketcap
243,91ย โ‚ฌ
Share price
4.37%
Change (1 day)
42.39%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -3,77ย โ‚ฌ

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -3,99ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of -9,03ย โ‚ฌ a decrease over its 2021 EPS that were of -7,00ย โ‚ฌ.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-3,77ย โ‚ฌ-58.25%
2022-9,03ย โ‚ฌ29.03%
2021-7,00ย โ‚ฌ-3.36%
2020-7,24ย โ‚ฌ-8.48%
2019-7,91ย โ‚ฌ7.67%
2018-7,35ย โ‚ฌ39.74%
2017-5,26ย โ‚ฌ12.94%
2016-4,65ย โ‚ฌ38.84%
2015-3,35ย โ‚ฌ-32.88%
2014-4,99ย โ‚ฌ259.44%
2013-1,39ย โ‚ฌ-31.25%
2012-2,02ย โ‚ฌ52.94%
2011-1,32ย โ‚ฌ30.77%
2010-1,01ย โ‚ฌ-8.77%
2009-1,11ย โ‚ฌ78.13%
2008-0,62ย โ‚ฌ-70.78%
2007-2,13ย โ‚ฌ99.09%
2006-1,07ย โ‚ฌ-43.88%
2005-1,90ย โ‚ฌ-82.33%
2004-10,78ย โ‚ฌ-59.23%
2003-26,44ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-1,65ย โ‚ฌ-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
36,30ย โ‚ฌ-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-7,61ย โ‚ฌ 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,26ย โ‚ฌ-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-1,64ย โ‚ฌ-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
3,63ย โ‚ฌ-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
3,09ย โ‚ฌ-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-1,94ย โ‚ฌ-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel